Reprieve Cardiovascular Presents Proposed HF Therapy at Med Tech Strategist Innovation Summit

Jim Dillon, President & CEO, Reprieve Cardiovascular, and Dr. Howard Levin, President, and Chief Medical Officer, Coridea, presented Reprieve’s innovative approach for heart failure therapy at the Med Tech Strategist Innovation Summit, April 9-11, in Dublin. The conference is recognized as the leading medical technology investment forum in Europe and brings together more than 450 leading experts, innovators, and key decision-makers to discuss the critical challenges facing the ever-evolving global med-tech community.

Mr. Dillon presented “First Automated Maintenance of Intravascular Volume” to a large audience. The 10 minute presentation provided an overview of the challenges around decongestion of acute heart failure patients, and demonstrates the therapeutic potential of Reprieve-Guided Diuretic Therapy. This technology represents the first automated workflow for diuresis and has the potential to help millions of patients worldwide.

Both Dr. Levin and Mr. Dillon participated on the panel CEOs/VCs & Entrepreneurs: How Deals Come Together. The discussion focused on how these groups join to fund emerging technologies and early stage companies.

Reprieve was featured as a “Start Up to Watch” in the April 3 issue of MedTech Strategist magazine.